ADC Therapeutics(US:ADCT) Prnewswire·2026-02-23 12:15Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate that targets and kills tumor cells by delivering a potent payload that binds to DNA [5]. - The FDA and EMA have approved ZYNLONTA for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [7][9]. Market Potential - ADC Therapeutics anticipates significant growth for ZYNLONTA starting in 2027, with potential peak revenue in the U.S. estimated to reach between $600 million to $1 billion annually, assuming compendia inclusion and regulatory approval [3]. - The confidence in ZYNLONTA's potential is bolstered by existing and upcoming clinical data, particularly in diffuse large B-cell lymphoma and other indolent lymphomas [3]. Company Background - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, focused on transforming treatment for patients through its portfolio, including ZYNLONTA [8]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to driving innovation in ADC development [10].